Johnson & Johnson announced that the FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of… read more.
Iptacopan is recommended, within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic anaemia. Iptacopan is only recommended if the company… read more.
Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has approved Keytruda Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the… read more.
NICE (UIK): Faricimab is recommended, within its marketing authorisation, as an option for treating visual impairment caused by macular oedema after central or branch retinal vein occlusion in adults…. read more.
Eli Lilly and Company announced the FDA approved Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who… read more.
Summit Therapeutics Inc. announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented… read more.
Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has announced the commercial launch of Gemtesa (vibegron) 75 mg tablets, a beta-3… read more.
The European Medicines Agency (EMA) has approved the pre-filled syringe for the administration of Eylea™ 8 mg (114.3 mg/ml solution for injection) in the European Union. The new… read more.
Gilead Sciences, Inc. announced that the FDA has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA)… read more.
Avadel Pharmaceuticals plc , announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime Lumryz versus a twice-nightly immediate-release oxybate treatment… read more.
Catheter Precision, Inc. announced that at the recently held European Society of Cardiology (ESC) Symposium, interim results demonstrating the use of VIVO in localizing the site of origin… read more.
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy, announced that the FDA has approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], for the treatment of toddlers… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
